Almirall, S.A.

MCE:ALM.MC

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

💄 Cosmetics

💊 Drugstores & Retail Pharmacies

Location

Spain

Market Cap

USD 2.64 B

Share Price

USD 12.30

Avg Daily Volume

140,564

Change (1 day)

-1.60%

Change (1 year)

16.85%

Change (YTD)

44.21%

Almirall, S.A. Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2024: USD 136.24 M

Almirall, S.A. Selling, General, and Administrative Expenses (SG&A) is USD 136.24 M for the year ending December 31, 2024, a 3.60% change year over year. Selling, general, and administrative (SG&A) expenses are the expenses related to the sales and marketing efforts, as well as general and administrative functions of a company.

Almirall, S.A. Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2023 was USD 131.50 M, a 189.67% change year over year.
Almirall, S.A. Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2022 was USD 45.40 M, a 1.98% change year over year.
Almirall, S.A. Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2021 was USD 44.52 M, a -11.50% change year over year.
Almirall, S.A. Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2020 was USD 50.30 M, a 0.62% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Selling, General, and Administrative Expenses (SG&A)	Research and Development (R&D) Expenses	Revenue	Revenue

MCE: ALM.MC

Almirall, S.A.

CEO	Mr. Carlos Gallardo Piqué
IPO Date	June 20, 2007
Location	Spain
Headquarters	Ronda Del General Miter, 151
Employees	2,026
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 💄 Cosmetics 💊 Drugstores & Retail Pharmacies

Description

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.